Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.
Launched by ST. PETERSBURG STATE PAVLOV MEDICAL UNIVERSITY · Dec 20, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific protein called myeloperoxidase might help predict outcomes for patients undergoing heart surgery. The goal is to understand how heart damage occurs during these procedures, which can help doctors improve care and recovery for patients with heart conditions.
To be eligible for the trial, participants should have ischemic heart disease (a condition where the heart doesn't get enough blood due to blocked arteries) or valve disease (problems with the heart's valves), and they must need surgery for these conditions. If you decide to participate, you’ll be contributing to important research while being monitored for your health during the trial. It's important to know that the trial is currently recruiting participants of all ages and genders, and the only reason someone might not be able to join is if they choose not to.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ischemic heart disease with indications for operation
- • valve disease with indications for operation
- • ischemic heart disease combined with valve disease with indications for operation
- Exclusion Criteria:
- • patient refusal
About St. Petersburg State Pavlov Medical University
St. Petersburg State Pavlov Medical University is a prestigious institution renowned for its contributions to medical education, research, and clinical practice. With a legacy dating back to 1897, the university is committed to advancing healthcare through innovative research and the development of cutting-edge clinical trials. Its multidisciplinary approach fosters collaboration among experts in various fields, ensuring the highest standards of scientific rigor and ethical compliance. By leveraging its extensive resources and expertise, St. Petersburg State Pavlov Medical University aims to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Petersburg, Non Us/Non Canadian, Russian Federation
Saint Petersburg, , Russian Federation
Patients applied
Trial Officials
Alexander Nemkov, PhD
Study Director
First Saint-Petersburg Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials